



# Micropathology Ltd

An independent, UKAS accredited, diagnostics and biomedical research laboratory



Accreditation number 9622

[https://www.ukas.com/wp-content/uploads/schedule\\_uploads/00007/9622%20Medical%20Single.pdf](https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/9622%20Medical%20Single.pdf)

## Laboratory User Handbook 11th September 2020

University of Warwick Science Park, Venture Centre  
Sir William Lyons Road, Coventry  
CV4 7EZ, United Kingdom

DX address: Micropathology Ltd  
Coventry 93CV DX6784501

[www.micropathology.com](http://www.micropathology.com)

Tel: +44 (0) 2476 323 222  
Fax: +44 (0) 2476 323 333

## Reviews

26<sup>th</sup> June 2017 – A reviews section added. Details added to the ‘Sending samples to the laboratory’ section detailing that it is the responsibility of the referring laboratories to ensure all samples are received to preserve their integrity. Details added of respiratory screen panel, Measles IgG antibodies and Lymphogranuloma venereum tests to test table. Updated external referral laboratories list. Staff list and external referral laboratory list updated.

6<sup>th</sup> July 2017 – Correction to spelling of Lymphogranuloma venereum in review section and test table. Also addition of throat swab to list of sample types for LGV.

21<sup>st</sup> July 2017 – Addition of a new test, HCV NS5a resistance, addition of a new member of staff and clarification of inhibitory urine samples for HSV and Chlamydia trachomatis in section 3.6iv. Clarification of urines as an unacceptable sample type for HSV testing and removal of ‘first pass’ urines as a sample type for Neisseria gonorrhoeae in the test table.

12<sup>th</sup> February 2018 - Amend TAT table following TAT audit. Replacement of CPA logo to UKAS accreditation logo. UKAS details added into the introduction section. Amended staff details. Added details into the transportation of samples area. Correction of sample types for HIV drug resistance. HBV AB detection sample types updated. Removal of External Referral laboratories section and removal of external serology tests from test table. Removal of Burkholderia cepacia detection and typing, Measles and Rubella IgG testing. Burkholderia cepacia typing removed from sequencing services. Updated EQA panel participation for 2017. Information added into the genetic testing that required for paternity testing. Formatting update of entire document.

15<sup>th</sup> March 2018 – Update to sample requirements for Hepatitis B E antigen, addition of whole blood as a sample type to Mycoplasma pneumoniae test. Added details to results section for release of results by telephone to other hospital departments. Details included re addition of tests from hospital departments to requesting tests sections. Amendment to retention of samples from several months to 6 weeks. Formatting of section titles to accurately reflect content in the contents table.

14<sup>th</sup> May 2018 – Changes to the test table include addition of Klebsiella pneumoniae test , addition of scheduling of serology tests, update of Streptococcus pneumoniae sample details, requirements to separate HBV, HCV and HDV serum / plasma from EWB within 24hours of taking blood sample to the test table. Detailed regarding of shipment of these samples also added.

Removal of external referral laboratories as the laboratory no longer refers samples. Sentence added to direct clients to ensure outer packaging box for samples is sealed.

21<sup>st</sup> May 2018 – Change of test name from 18srRNA fungal gene detection and sequencing to Pan fungal DNA detection / sequencing. Additional test requests - Request to users to ask them to confirm request for an additional sent by email, if they have not received a reply within 24hours.

6<sup>th</sup> July 2018 – Amendment to size of UKAS logo on front page to 20mm. Addition of user feedback to section to include the companies house registration number and details of how to provide feedback on the service. Update of test table HHV6 and HHV6 quantitation to remove requirement to send whole blood as preferred by removal of \*\*\*. Addition of ‘research only’ to particular tests in test table. Removal of Burkholderia cepacia and cervical cytology from test table.

Update of sample requirements for tests.  
Serology sample stability data added for antigens and antibodies.  
Addition of 'at users request' to the HSV typing assay for eye and oral swab samples and clarification of exactly what samples can be tested for HSV typing.  
Clarification of additional test requests to test requests table. Non-critical to be made by email.  
Critical test requests to be made by telephone.  
Updated staff list.  
Update of information required on request form and sample based on IBMS criteria.  
Rework of the factors affecting assays section to added clarity.

3<sup>rd</sup> October 2018 revisions

Section 2.3 - Updated staff list.

Test table - Change to limit of sensitivity for HCV RNA and HCV RNA quantitation assays. Alterations to antibodies to HepE antigen assay sample requirements and associated stability in relevant stability table. BAL removed from HHV6.

Section 3.2 - Sending samples to the laboratory section reworked for clarity to detail modes of sample transportation and sample packaging.

Additional examination section in table in section 3.3 clarified to denote critical and non-critical tests.

Table 3.3 Addition of text 'strongly recommended' added to URGENT test section in table.

Section 3.6 addition of Category III organisms to samples that will undergo additional extraction procedures.

Creation of new section 3.7 – addition of preferable sample volume 500µL to facilitate additional extraction and testing, and instructions to send sufficient sample if requesting multiple tests.

Section 3.8i nucleic acid based tests - Addition of low sample volume details for nucleic acid tests in factors affecting samples section.

Section 3.8i nucleic acid based tests inhibition section - Removal of urines which may exhibit inhibition.

Section 3.8i nucleic acid based tests HIV-1, HBV and HCV section – Further detail in HIV-1, HBV and HCV section regarding separation of plasma from EDTA whole blood within 24hours of blood draw.

Reformatting of headings throughout document.

Removal of rubella antibody ranges from table in section 3.10.

4<sup>th</sup> October 2018 – Addition of Bartonella genus test to test table.

5<sup>th</sup> October 2018 – Addition of laboratory manager role in staff section. Addition of further details for sample volume required for HCV detection and quantitation tests to test table.

6<sup>th</sup> December 2018 – Addition of new staff. Addition of new test, UL54 for CMV drug resistance in test table. Addition of missing 'unaccredited logo' from Bartonella and HCV assay in test table. Correction of spelling of Tropheryma whipplei in test table. Updated EQA panels for 2018. Amended payment details to request BACS payments only in section 8. Clarification of testing urgent samples in section 3.2i and addition of request for users to inform the laboratory of possible infection with Cat3 organisms in request tests section.

7<sup>th</sup> December 2018 – Correct spelling of Tropheryma whipplei in test table.

13<sup>th</sup> February 2019 – Addition of new member of staff Dr Frances Pitt. Addition of details regarding sample retention. Increase in TAT for EV.Rh differentiation details added to subtext for Test table. Details for additional CtNg testing to LGV testing also specified in test table additional text. Section 3.6 and 3.7 switched around. Removal of Q80K from test table as no longer offered.

14<sup>th</sup> February 2019 - Addition of Michael Steele to staff list. Addition of whole blood to validated sample types in CMV drug resistance UL54 and UL97. Update of table page references.

1<sup>st</sup> April 2019 – Update of staff list to include Dr Mark Atkins and update job roles. Update of pan fungal test name to include (18S) in test table. Clarified that users should ensure samples are received by 9.30am to ensure that samples results will be released within the expected test turnaround times. Formatting of section 3.3. Add details of testing in combination of Ct and Ng into test table information.

26<sup>th</sup> April 2019 – Additional test added to test table to include *Mycoplasma genitalium* macrolide resistance. HHV6 test now detailed as detecting 6A and 6B types. Update of CMV drug resistance tests. Test table pagination reference in handbook updated throughout.

1<sup>st</sup> May 2019 – Addition of HHV7 quantitation tests to test table and Legionella pneumophila as a 'research only' test to test table.

7<sup>th</sup> May 2019 – Addition of a new staff member to staff list and amendment to Respiratory screen tests.

3<sup>rd</sup> June 2019 – Add details to the test table key that a maternal blood sample should be sent when testing infants <18 months old for HIV-1 proviral DNA / RNA. HBV assay details updated as new assay awaiting accreditation. Additional volume details added to hepatitis related tests in the test table.

12<sup>th</sup> June 2019 – Amended limit of detection of the HBV quantitation assay from 50IU/mL to 16IU/mL as detailed incorrectly.

6<sup>th</sup> August 2019 – Amendment to staff list and job titles. Alteration to sample volumes in test table. Change of name of forensic tests to human identification and removal of paternity test.

15<sup>th</sup> August 2019 - Amendment to name of test from "Human identification DNA profiling" to "Genetic profiling for human identification and relationship testing (Human ID DNA profiling)" and amendment of accompanying comment to "for identification of human remains, comparison of clinical samples and relationship testing (e.g. paternity, sibship or zygosity testing)". Removed forensic DNA profiling and paternity testing from list under 3.11 and replaced with genetic profiling for human identification and relationship testing. Detailed that genetic profiling for human identification and relationship testing can be performed on various sample types, but users should contact the laboratory for advice.

4<sup>th</sup> October 2019 – Update to staff list. Removal of use of cotton tipped swabs in factors affecting PCRs. Update the safe transport of samples section to include further and correct details for sample transport. Update of test table to alter TAT for Treponema pallidum, scheduled serology tests, addition of measles IgG and aspergillus antigen (Galactomannan) tests. Sample stability table updated. Serology tables updated with new test data.

29<sup>th</sup> October 2019 - Update of test table list as many tests are now UKAS accredited. Added new member of staff Suhayl Mulla to staff list. Mycobacterium TB / complex TAT increased to 4 days.

21<sup>st</sup> January 2020

Amend sample types to HBV drug resistance mutation screen, Mycobacterium genus / TB test, Mycoplasma pneumoniae and Measles tests and updated test table caveats in A – Z

table. Update staff list. Updated EQA list to indicate 2019 panels participated in. Updated sequencing service list.

3<sup>rd</sup> February 2020 – Update to *Pneumocystis jiroveci* test to state 'awaiting UKAS accreditation. Added details regarding forwarding / returning samples to laboratories.

3<sup>rd</sup> March 2020 - Removal of Measles IgG antibody test. Removal of CSF from Polyoma BK qualitative and quantitative tests. Update of requirements for matching samples and request form. Removal of junior software developer Ashley Howells.

24<sup>th</sup> March 2020 - Add new test novel Coronavirus-SARS2 to the test repertoire. Change the status of Legionella pneumophila and Adenovirus DNA detection and quantitative test to awaiting accreditation

Indicate that some results for Mycoplasma pneumoniae and Chlamydia pneumoniae may be reported following testing on the NxTAG® Respiratory Pathogen Panel, which has been validated and is awaiting accreditation from UKAS.

Addition of a new member of staff – Kyle Billing.

Addition of COVID testing on a weekend in test request table section 3.3.

26<sup>th</sup> March 2020 – Amendment to new test Coronavirus-SARS-CoV-2 name. Also this test is included in the extended respiratory screen.

2<sup>nd</sup> May 2020– Updated sample types Group A Streptococci and Group B Streptococci assays, HTLV-1 DNA/RNA, Brucella DNA and Borrelia DNA tests in test table.

Updated Acanthamoeba test to state 'awaiting UKAS accreditation'.

Accessions manager updated in staff list.

15<sup>th</sup> May 2020 – added details of test requests extracted on the KingFisher Flex extraction platform.

Removed Daniel Hand as a staff member

20<sup>th</sup> May 2020 – Update of tests extracted on new KingFisher Flex system.

Update of pagination for test table.

Addition of full date on cover page.

17<sup>th</sup> June 2020

Remove Awaiting UKAS accreditation for particular tests and extraction procedure details

Added awaiting accreditation to Mycoplasma genitalium macrolide resistance.

Added 'research only' to the HBV Pre core / core test.

Remove details about urgent testing of certain tests affecting TAT.

Added detail to requests for results on the telephone.

22<sup>nd</sup> June 2020

Update section regarding results sending to clients.

13<sup>th</sup> July 2020

To update staff list with the new students

20<sup>th</sup> July 2020

To clarify sample types for Coronavirus SARS CoV-2 tests

9<sup>th</sup> September 2020

Mark West Nile Virus, Pseudomonas aeruginosa and Bartonella tests as 'Awaiting accreditation'.

Updated staff list

Updated length of time samples are stored for.

Removal of measles IgG test.

Added new Coronavirus SARS CoV-2 test to extended respiratory screen.

11<sup>th</sup> September 2020

Mark Polyoma BK tests as 'Awaiting accreditation'.

# Table of contents

1.	Introduction .....	8
1.1	The Laboratory and outline of services .....	8
1.2	Laboratory policy .....	8
1.3	Using this handbook .....	8
2.	Laboratory and Staff .....	8
2.1	Laboratory opening times .....	8
2.2	Location and visitors .....	9
2.3	Staff .....	9
3.	Diagnostic and Advisory Services .....	10
3.1	Information and enquiries .....	10
3.2	Sending samples to the laboratory .....	10
3.2i	Prompt transport of specimens .....	10
3.2ii	Packaging and sending samples .....	11
3.3	Requesting tests .....	11
3.4	Request forms and sample identification .....	13
3.5	Patient confidentiality .....	14
3.6	Sample volume and handling .....	14
3.7	List of tests available, target turnaround times, sample types and prices ..	14
3.8	Factors affecting assays .....	25
3.8i	Nucleic acid based tests .....	25
3.8 ii	Serology samples .....	26
3.10	Reference values for Serological assays .....	27
3.11	Human genetic testing .....	28
3.11i	Consent for Genetic Testing .....	29
3.12	Sequencing service .....	29
4.	Additional services .....	29
5.	Quality Assurance .....	30
5.1	External QA schemes .....	30
5.2	Accreditation .....	32
6.	Results and Reports .....	32
7.	User Feedback and Complaints procedure .....	33
8.	Payment for services .....	33
8.1	Terms of Payment .....	33
8.2	Acceptable Methods of payment .....	33

# 1. Introduction

## 1.1 The Laboratory and outline of services

Micropathology Ltd provides a clinically supported service for the rapid diagnosis of infectious disease and host responses to infection. This service includes contract research, clinical trials for external organizations and in-house assay development.

Micropathology Ltd also provides genetic profiling for human identification and relationship testing molecular genetics, sequencing services and also undertakes biomedical research covering various aspects of human and veterinary pathology.

These services are offered to all hospitals, NHS laboratories, General Practitioners and private medical laboratories throughout the UK and abroad. The service is also available to HM Coroners ( body identification) and University research groups.

Ongoing contact with all our clients is welcome and we are happy to discuss how we may help to meet the needs of both existing and new clients.

The laboratory is UKAS accredited to ISO15189:2012 (Laboratory reference number 9622) and participates in all appropriate external quality assurance schemes. The published scope is available on [https://www.ukas.com/wp-content/uploads/schedule\\_uploads/00007/9622%20Medical%20Single.pdf](https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/9622%20Medical%20Single.pdf).

An 'out of hours' on-call clinical advice service is available for healthcare professionals to discuss specific or general matters concerning infectious disease or vaccination.

## 1.2 Laboratory policy

The directors and staff work to the highest possible standards in all aspects of the company's business. We subscribe to both ISO15189:2012 international standard of accreditation and quality assurance schemes in order to maintain excellence in all our undertakings. We are strongly committed to research and to the provision of training for all members of staff.

## 1.3 Using this handbook

This handbook is designed to assist clients in the provision of our services. Further information is available on [www.micropathology.com](http://www.micropathology.com) or by telephoning the company.

# 2. Laboratory and Staff

## 2.1 Laboratory opening times

The laboratory is open between the hours of 08.30 to 17.30 Monday to Friday, with telephone service in the laboratory from 9.00 – 17.45 hrs, when staff are available for advice, information, specimen reception and processing. Outside of these hours a



telephone service is provided for results and clinical advice. We also receive samples on Saturday mornings which are processed the following working day.

A schedule of working arrangements over Easter, Christmas and New Year, and other bank holidays (those recognised in England and Wales only) throughout the year is faxed out to existing customers in advance and by email to registered website users.

## 2.2 Location and visitors

Micropathology Ltd is located between the M6 and the M40, 4 miles outside of Coventry off the A45. Car parking is available at the Venture Centre and visitors are requested to report to reception in the entrance foyer where they will be issued with a visitor's pass. It is essential to make an appointment in advance.

## 2.3 Staff

Medical / Laboratory Director	Prof. Colin Fink
Scientific / Laboratory Director	Dr David Burnett
Consultant Virologist / Microbiologist	Dr Mark Atkins
Clinical Scientist (Genetics)	Dr Sarah Ball
Clinical Scientist (Microbiology)	Dr Jennifer Morris-Cottell
Clinical Scientist (Virology)	Dr Paul Scott
Quality Manager	Dr Andrea Collins
Quality Lead	Ms Nagela Ford
Clinical Scientist & Company Representative	Ms Heather Smith
Laboratory Manager / Post-doctoral scientist	Dr Mark Collery
Post-doctoral Scientist / Health & Safety Co-ordinator	Dr Sian Davies
Microbiology manager / Post-doctoral Scientist	Dr John Thomas
Virology Manager / Training officer Post-doctoral Scientist	Dr Edward Sumner
Accession managers	Dr Mark Collery, Ms Annie Fletcher
Serology Manager / Post-doctoral Scientist	Dr Penny Reid
Sequencing manager / Post-doctoral Scientist	Dr Jennie Holden
Equipment manager / Post-doctoral Scientists	Dr Ronan Calvez, Dr Ollie Smith

Post-doctoral Scientists

Dr Emily Hudson, Dr James Edwards-Smallbone, Dr Michael Steele, Dr Frances Pitt, Dr Ollie Smith, Dr Donald Fraser, Dr Suhayl Mulla, Dr Andrew Taylor, Dr Jack Hassall.

Post-doctoral Scientist/IT manager

Dr Peter Millichap

Research Post-doctoral Scientists

Dr Leo Calvo-Bado, Dr Marie Voice, Dr Richard Fetherston

IT systems architect

Mr Pete Matthews

Software developer

Mr Kyle Billing

Post-graduate scientists

Miss Rhiannon Weale, Miss Amelia Brett, Miss Annie Fletcher, Miss Ellie Philips, Miss Jay Drury.

Intercalated year students

Coren Gibson, Jennifer Blackmore, Rebekah Harrison, Gemma Harvey, Zahrah Beg, Ella Finnie, Hannah Leek

Company accountant

Mrs Weiping Barrett

Administrative assistant

Ms Dawn Mason

Administration support

Dr Sue Webster

Administration and accounting support

Zhiwen Luo

### **3. Diagnostic and Advisory Services**

#### **3.1 Information and enquiries**

For general information, consultation on appropriate investigation and sample testing, or enquiries regarding results and their interpretation please contact Micropathology Ltd on +44 (0) 2476 323222, or alternatively email [info@micropathology.com](mailto:info@micropathology.com) where enquiries can be answered or referred to the appropriate personnel. Clinical advice for hospital based personnel, General Practitioners and their nursing staff is also available on the above number, including out of hours.

#### **3.2 Sending samples to the laboratory**

##### **3.2i Prompt transport of specimens**

It is the responsibility of the sender to comply with courier, UK postal or international safety regulations for clinical specimens transport.

To ensure prompt testing of samples and release of results within the published test turnaround times (Pages 15-24), samples should arrive into the laboratory by 9.30a.m. The use of a courier service (Dx) is recommended, especially for URGENT and CRITICAL samples.

Samples sent by post arrive after the days sample processing has begun. In these instances samples will be processed on the next working day and not on the day of receipt into the laboratory. This will affect the test turnaround time between receipt into the laboratory and results reporting.

### 3.2ii Packaging and sending samples

To preserve the continued integrity of the specimen, it is the customers responsibility that samples sent to Micropathology Ltd arrive safely and securely in a prompt manner. The results obtained for testing of samples is based upon the quality of the sample(s) as they are received at the laboratory

Infectious substances assigned to Category B (UN3373) can be transported by specialised couriers or the Royal Mail, provided they comply with the required packaging instruction. Please refer to <https://www.un3373.com/category-biological-substances/category-b/> for further details. Always clarify with your provider before shipping.

Request forms must be placed between the secondary container and the outer shipping container. Request forms **should not** be placed inside the secondary container.

Users sending samples containing, or suspected to contain Category III organisms or are from a patient suspected to have Creutzfeld-Jakob disease, should clearly mark the referral form with the details of the potential hazard. This ensures that the sample can be handled appropriately upon receipt into the laboratory. In addition, the secondary specimen container can be marked with a hazard sticker to alert staff of potential hazards prior to opening.

Please ensure the outer packaging is addressed correctly to ensure prompt delivery of specimens. We will supply mailing or DX labels, if required. Details of senders should be attached to this box. Secondary and outer packaging materials will be returned for reuse if requested. This service does incur a standard rate postal charge

## 3.3 Requesting tests

Each test requested shall be considered an agreement. The company have a service level agreement for users and will consider any external service level agreements. Micropathology Ltd. shall inform users of any change to service which will impact on

the examination result. Requests from hospital departments other than the referring laboratory must ensure the referring laboratory is aware of the additional request.

TEST REQUEST	Service provided	Additional information
<b>ROUTINE</b>	We accept and test many different kinds of clinical samples including fresh and fixed tissue samples. Please refer to the specimen tables for a list of appropriate samples for test types.	<b>Late arriving samples (After midday) will not be processed until the next working day unless by prior arrangement or are considered urgent. This will therefore affect the expected TAT.</b>
<b>ADDITIONAL examinations *</b>  <b>Samples received <u>within</u> 24hrs (already under investigation)</b>	Additional <b>non -urgent</b> test requests can be requested by telephone, fax or email <a href="mailto:info@micropathology.com">info@micropathology.com</a> .  Additional <b>critical</b> test requests should be made by telephone 024 76323222.  Additional test requests received after midday, on samples currently under investigation, may be subject to processing and testing on the next working day.  If sending a request by email, please contact to the laboratory within 24 hours if you have not received a email reply to your request.	Please <b>do not</b> send requests to personal email accounts as this may result in a delay in responding to your request and subsequent testing
<b>ADDITIONAL examinations *</b>  <b>Samples received <u>more than</u> 48 hours ago (archived samples)</b>	Specimens are archived at -20°C for 2 weeks. Additional examinations may be requested on these samples where there is sufficient volume remaining.	Additional requests on samples received more than 48hours previously may require full sample extraction and processing and will attract full sample costs.
<b>URGENT requests</b>	Many off our samples are reported the same day. If something is especially urgent please advise.  <b>PLEASE DO NOT SEND URGENT SAMPLES BY POST DUE TO THE LATE ARRIVAL OF THE POST. A COURIER IS STRONGLY RECOMMENDED AS A MORE TIMELY MODE OF TRANSPORT FOR URGENT SAMPLES.</b>	Please enquire BEFORE requesting this service; we may be able to offer a routine assay that is as fast on the day at no extra cost.
<b>WEEKEND analysis</b>	For weekend urgent analysis, please telephone to make special arrangements. The laboratory are currently running a diagnostic service at the weekend for CoVID. Please contact the laboratory for details.	We place a weekend premium charge for urgent analysis; please enquire by telephone if you are considering using this service

Please note: If you do NOT refer anything to us on a routine basis please contact [info@micropathology.com](mailto:info@micropathology.com) or telephone +44 (0) 2476 323222, to confirm we hold the correct result destinations (Fax numbers, email addresses etc).

### 3.4 Request forms and sample identification

**In all requests for testing, clinical information is an aid to laboratory diagnosis.**

A request form must accompany and identify all specimens. Your own locally available pathology form is acceptable or a customisable Micropathology Ltd request form is available to download from our web site. **The origin of the request must be an authorised body and not an individual member of the public.** Evidence of informed consent by patient or parent/guardian is required for clinical genetics tests.

To ensure unequivocal identification, samples and request forms **MUST** contain the minimum essential identification criteria. If insufficient information is not provided to ensure unequivocal traceability, samples may be rejected without analysis or referred back to the requesting practitioner.

The sample and request form must contain matching information and contain the following:

	Essential	Desirable
Sample*	<ol style="list-style-type: none"> <li>1. Patient's full name or unique code identifier</li> <li>2. Date of birth and / or hospital number</li> <li>3. NHS, CHI or health and care number</li> </ol> <p><i>Barcodes on the sample do not replace full sample labelling but if used must be identical to barcodes on the request form.</i></p>	<ol style="list-style-type: none"> <li>1. Date and time of sampling</li> <li>2. Nature of sample i.e. left eye swab</li> <li>3. Lab reference number</li> </ol>
Request form*	<ol style="list-style-type: none"> <li>1. Patients full name or unique code identifier</li> <li>2. Date of birth and / or hospital number</li> <li>3. NHS, CHI or Health and Care Number</li> <li>4. Gender</li> <li>5. Lab reference number</li> <li>6. Sample type</li> <li>7. Investigation(s) required</li> <li>8. The full postal address of the requesting authority *</li> <li>9. A contact telephone number</li> <li>10. A contact name, or consultant's name where possible</li> <li>11. Secure email/fax/postal details to which the results will be sent.</li> </ol>	<ol style="list-style-type: none"> <li>1. Clinical information including relevant treatment/medication and if a female is known to be pregnant</li> <li>2. Date and time of sample</li> </ol>

\*Information taken from IBMS guidance on patient sample and request form identification criteria 2019 <https://www.ibms.org/resources/documents/ibms-guidance-on-patient-sample-and-request-form-identification/>

*The Health and Care Number is a 10 digit number randomly selected and allocated to everyone in Northern Ireland. Individuals registered with a Scottish GP practice has their own unique ten-digit number Community Health Index (CHI) number.*

\* Failure to provide sufficient contact referral laboratory details will result in samples being enter into the LIMS as 'Micropathology Ltd 'unidentified source' until such time as a client contacts the laboratory seeking results.

### 3.5 Patient confidentiality

All samples received are treated in the strictest confidence and are anonymised upon receipt into the laboratory. Prof. Colin Fink is responsible for protecting the confidentiality of the patient and service-user information. We are registered with the Information Commissioners Office and comply with the obligations and duties under the General Data Protection Regulation (EU) 2016/679 and Freedom of Information Act.

### 3.6 Sample volume and handling

Unless stated otherwise in the test table, please send at least **200µL** of liquid sample for testing, **preferably 500µL to facilitate additional extraction and testing**. Low volume samples may be diluted and tested, but reports will bear a caveat regarding the potential effect on assay sensitivity. Sending sufficient sample is imperative when requesting multiple tests.

For tissue samples; please send a matchstick head sized piece of the appropriate tissue in a sterile container. If you are unsure of the suitability of a particular sample, please contact us.

Bilateral eye swabs, and nose and throat swabs may be combined in the same tube with the same accession number if the client has assigned them the same laboratory number and we cannot distinguish between them. If they have the same laboratory number but are clearly labeled 'left' and 'right' eye then they will be assigned different accession numbers. If this is not preferred please state this on the sample request form.

Portions of samples are retained for 2 weeks to facilitate repeat or additional testing. The exception to this are wax embedded samples which are retained indefinitely. We do however, advise sending block shavings rather than the whole wax block.

Samples may be stored for longer if there is an explicit agreement between the user and Micropathology Ltd. This can be achieved through a service level agreement. Please contact the laboratory for further information.

### 3.7 List of tests available, target turnaround times, sample types and prices

We offer a comprehensive range of assays for the rapid detection of pathogens and host responses. Please refer to the following table on pages 15-24 for details of tests offered, test turnaround time and appropriate validated sample types. These are further detailed on the laboratory schedule of accreditation [https://www.ukas.com/wp-content/uploads/schedule\\_uploads/00007/9622%20Medical%20Single.pdf](https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/9622%20Medical%20Single.pdf). Other unvalidated

sample types can be tested but the sensitivity cannot be guaranteed to be at the same limit of detection.

Test turnaround time is based on a Monday to Friday working week. Saturday/Sundays are not included in TAT calculations. Some tests are scheduled throughout the week and these are detailed in the test table but may be performed at other time points depending on test requests. All other assays are run on a daily basis.

The company expect that 90% of test results will be available with the defined TAT. However, a proportion of tests require repeat for confirmation of rare / weak or 'off scale' positives and will result in a delay in reporting results. Additional tests may be added late in the day (Post midday) due to external or internal factors and requests. In these instances results for tests may incur a delay in results being made available to users and will affect TAT.

Additionally, those samples requiring special extraction procedures (Tissues, post mortem samples, stools, eye samples, Category III organisms) due to the nature of the sample or test requested, may incur a delay in reporting results to that of the published TAT.

We will consider any project for the development of new molecular diagnostic assays, with the aim of improving the sensitivity or speed of diagnosis over existing methods. Please contact the laboratory for further information/discussions.

Prices can be accessed by users registered on our website.

Users will be contacted if Micropathology Ltd do not offer a requested test. Micropathology Ltd currently do not refer work to 3<sup>rd</sup> party laboratories. Samples will be returned or forwarded to a laboratory for further testing at a user's request. In this instance samples will incur a postal charge as detailed in the test table.

Abbreviations used in test table

ACD – Acid citrate dextrose  
BAL – Bronchioalveolar lavage  
CPD – Citrate phosphate dextrose  
CPDA – Citrate phosphate dextrose adenine  
CP2D - Citrate phosphate double dextrose  
CSF – Cerebrospinal fluid  
EDTA - Ethylenediaminetetraacetic acid

**Test repertoire, test turnaround, validated sample types.**

<b>Tests available</b>		
<b>Test</b>	<b>Target turn-around</b>	<b>Validated Sample types</b>
Client sample postage: returns and forwarding to PHE	Next day	Any <sup>ψ</sup>
16S rRNA bacterial gene detection	2 days	Any (inc. fixed tissue) preferably from normally sterile sites
16S rRNA bacterial gene sequencing	2 days	PCR product (see detection above) or bacterial culture
Pan fungal (18S) DNA detection	3 days	Any (inc. fixed tissue) preferably from normally sterile sites
Pan fungal (18S) DNA sequencing	3 days	PCR product (see detection above) or fungal culture
Acanthamoeba DNA ▲	2 days	For eyes - Corneal scrape, swab or contact lens, contact lens solution Meningitis - CSF
Adenovirus DNA ▲	Next day	Vitreous fluid, eye fluid, serum, skin swab, blood, plasma, urine, bronchial washings, NPA, swab (Nose, throat, eye), CSF, pericardial fluid, bone marrow.
Adenovirus DNA quantitation	Next day	EDTA/citrated whole blood, CSF and plasma
Adenovirus typing (Research only)	5 days	PCR product generated in-house from the sample types detailed for Adenovirus DNA
Alpha-1 antitrypsin genotyping	5 days	EDTA/citrated whole blood
Aspergillus genus DNA	5 days	EDTA/citrated whole blood/ lower respiratory sample ((BAL, bronchial washings, sputum)
Aspergillus antigen (Galactomannan) ▲	This test is scheduled on Wednesdays	Serum, BAL
Bartonella genus ▲	2 days	EDTA whole blood, tissue
Bocavirus	Next day	Any upper / lower respiratory specimen (sputum, BAL, NPA, nasopharyngeal swab etc), BAL and NPA preferred
Bordetella pertussis DNA	2 days	NPA, perinasal and nasopharyngeal swab
Borrelia genus	2 days	EDTA/citrated whole blood, CSF, tissue, serum
Brucella genus DNA	3 days	EDTA/citrated whole blood, CSF, tissue, serum <b>We do not accept cultures for safety reasons</b>
Candida albicans DNA	2 days	EDTA/citrated whole blood, CSF, eye fluid



Tests available		
Test	Target turn-around	Validated Sample types
Chlamydia pneumoniae DNA <b>See ○ below (▲NxTAG® results only)</b>	Next day	Any respiratory specimen (sputum, BAL, NPA, nasopharyngeal swab etc), BAL and NPA preferred
Chlamydia psittaci DNA	2 days	BAL, nasopharyngeal swab
Chlamydia trachomatis DNA <b>If sending for confirmation in accordance with BASHH guidelines, please telephone the laboratory for further information.</b> Individual requests for Ct are always tested in combination with Ng respectively.	2 days	Eye swab, throat swab For genitourinary: Female: Endocervical, vaginal or rectal swab, 'Thin prep' endocervical cellular specimens. Male: Urethral swab, first pass urine, rectal swab
Clostridium difficile (Research only)	3 days	Stool
Coronavirus 229E, HKU1, NL63 or OC43	Next day	Any upper / lower respiratory sample
Coronavirus – SARS-CoV-2 ▲	Same day	Any respiratory sample can be tested but a throat swab taken by a medical professional is the recommended sample type
Coxiella burnetii	Next day	EDTA whole blood, BAL and tissues. <b>We do not accept cultures for safety reasons.</b>
Cryptococcus neoformans DNA	Next day	CSF, EDTA whole blood
Cytomegalovirus DNA	Same day	EDTA/citrated whole blood, urine, serum/EDTA plasma, eye fluid, tissue, biopsy or respiratory specimen - BAL preferred. Pregnancy – EDTA whole blood, amniotic fluid, cervical swab, serum/plasma
Cytomegalovirus DNA quantitation	Same day	EDTA/citrated whole blood, urine, serum/EDTA plasma, eye fluid
Cytomegalovirus drug resistance (ganciclovir, foscarnet or cidofovir) (UL97 and UL54)	5 days	Whole blood, serum / plasma
Enterovirus RNA	Next day	CSF, swab, stool, tissue, serum, plasma, EDTA/citrated whole blood - may be useful in suspected meningitis cases
Enterovirus typing (Research only)	3 days	CSF, EDTA/citrated whole blood, stool, respiratory samples, tissue, serum, plasma
Epstein Barr Virus DNA	Same day	EDTA/citrated whole blood, CSF, urine, serum, plasma, biopsy
Epstein Barr Virus DNA quantitation	Same day	EDTA/citrated whole blood, CSF, urine, serum, plasma
Escherichia coli DNA	2 days	CSF, EDTA/citrated whole blood
Factor V Mutation + Prothrombin	5 days	EDTA / citrated whole blood
Genetic profiling for human identification and relationship testing (Human ID DNA	15 days	Bone/teeth

Tests available		
Test	Target turn-around	Validated Sample types
Profiling)- extraction from bone or teeth - <b>For identification of human remains, comparison of clinical samples and relationship testing (e.g. paternity, sibship or zygoty testing)</b>		
Genetic profiling for human identification and relationship testing (Human ID DNA Profiling) - <b>For identification of human remains, comparison of clinical samples and relationship testing (e.g. paternity, sibship or zygoty testing)</b>	10 days	Cheek swab, EDTA/citrated whole blood, tissue, serum, fixed tissue (least preferred sample), personal items (Hairbrush, comb, razor)
Group A Streptococcus (S.pyogenes) DNA	Next day	CSF, EDTA/citrated whole blood, tissue, joint fluid and pleural fluid
Group B Streptococcus (S. agalactiae) DNA	Next day	CSF, EDTA/citrated whole blood, tissue, joint fluid, pleural fluid
Haemochromatosis H63D C282Y	5 days	EDTA / citrated whole blood
Haemophilus ducreyi DNA	2 days	Swab
Haemophilus influenzae/parainfluenzae DNA	Next day	CSF, EDTA/citrated whole blood.
HBV Core/PreCore Mutations (Research only)	5 days	Serum/plasma
Hepatitis B core antibody (Tests schedule Monday and Thursday)	3 days	Li-heparin, Na-heparin, K2-EDTA, K3-EDTA, ACD, CPD, CP2D, CPDA and Na-citrate plasma
Hepatitis B e antibody (Tests schedule Monday and Thursday)	3 days	Li-heparin, Na-heparin, K2-EDTA, K3-EDTA, ACD, CPD, CP2D, CPDA and Na-citrate plasma
Hepatitis B e antigen (Tests schedule Monday and Thursday)	3 days	Serum preferred or Na-heparin*, Li-heparin*, K2-EDTA, K3-EDTA, ACD, CPD, CP2D, CPDA and Na-citrate plasma.
Hepatitis B drug resistance mutation screen ♦	5 days	<b>At least 0.6mL</b> Serum/plasma <b>Please supply viral load if available.</b>
Hepatitis B surface antibody	3 days	Serum preferred or K2/K3EDTA plasma **

Tests available		
Test	Target turn-around	Validated Sample types
(Tests schedule Monday and Thursday)		
Hepatitis B surface antigen (Tests schedule Monday and Thursday)	3 days	Serum preferred or Li-heparin*, Na-citrate, K2/K3- EDTA, CPDA, CPD, CP2D, ACD, citrate plasma.
Hepatitis B surface antigen quantitation (Tests schedule Monday and Thursday)	3 days	Serum preferred or Li-heparin*, Na-heparin*, K2-EDTA, citrate plasma
Hepatitis B virus DNA (<16IU/mL) ♦	Next day	<b>At least 0.6mL</b> serum/plasma
Hepatitis B virus DNA quantitation (<16IU/mL) ♦	Next day	<b>At least 0.6mL</b> serum/plasma
Hepatitis B genotyping ♦	3 days	<b>At least 0.6mL</b> serum/plasma
Hepatitis C antibody (EIA) (Tests schedule Monday and Thursday)	3 days	Serum preferred or Li-heparin*, K2/K3-EDTA, Na-heparin, Na-citrate, CPDA, CPD, CP2D, and ACD plasma.
Hepatitis C antibody (RIBA) (Tests schedule Monday and Thursday)	3 days	Serum preferred or Li-heparin*, citrate or EDTA plasma
Hepatitis C NS5A resistance testing ♦	4 days	<b>At least 0.6ml</b> serum/plasma Please supply viral load if available.
Hepatitis C genotyping ♦	3 days	<b>At least 0.6mL</b> serum/plasma Please supply viral load if available.
Hepatitis C virus RNA (<15IU/ml) ♦	Next day	<b>At least 0.7ml serum/plasma, 1ml is preferable.</b> Please send more sample if other tests are required.
Hepatitis C virus RNA quantitation (<15IU/ml) ♦	Next day	<b>At least 0.7ml serum/plasma, 1ml is preferable.</b> Please send more sample if other tests are required.
Hepatitis D virus RNA ♦	3 days	<b>At least 0.6mL</b> serum/plasma This assay should always be reviewed in conjunction with HBV investigations.
Hepatitis D virus RNA quantitation ♦	3 days	<b>At least 0.6mL</b> serum/plasma. This assay should always be reviewed in conjunction with HBV investigations.
Hepatitis E virus RNA	2 days	<b>At least 0.6mL</b> serum/plasma, CSF, whole blood, stool
Hepatitis E virus RNA quantitation	2 days	<b>At least 0.6mL</b> serum/plasma, CSF, whole blood
Herpes Simplex virus DNA	Next day	CSF, AC tap, EDTA/citrated whole blood, vesicle fluid, skin/eye/corneal vesicle/lesion swab, tissue (Biopsy and fixed included). Any respiratory specimen (sputum, BAL, NPA, nasopharyngeal swab etc) . aqueous / vitreous humour. Genitourinary - For female: Endocervical or vulval lesions sample area with a swab and place into viral transport media (VTM). Male: Penile lesions - Penile swab placed into

Tests available		
Test	Target turn-around	Validated Sample types
		VTM. Urine is not a recommended sample type for diagnosis of infection in male or females. Pregnancy – vulval/vaginal swab
Herpes Simplex Acyclovir drug resistance	5 days	HSV-1 positive samples, including CSF, Corneal scrapes, vesicle fluid, swabs, and whole blood
Herpes Simplex virus types I & II typing	Next day	Performed routinely on positive HSV samples (including CSF, amniotic fluid, EDTA/citrate-whole blood, vesicle fluid, skin/lesion swab, tissue samples and biopsies, any respiratory specimen (sputum, BAL, NPA, nasopharyngeal swab etc). <b>HSV positive eye samples and oral swabs are typed upon request.</b> Specific requirements for genitourinary samples: Males: Penile lesions-penile swabs placed into VTM. Females: Endocervical or vulval lesion swabs placed into VTM. In pregnancy, vulval/vaginal swabs placed into VTM. <b>Urine</b> is not a recommended sample type for the diagnosis of infection in male or female patients.
HIV I & II antibody and p24 antigen (EIA) (Tests schedule Monday and Thursday)	3 days	Serum preferred or Li-heparin*, EDTA, ACD, CPD, CP2D, CPDA and Na-citrate plasma
HIV I & II antibody (LIA) (Tests schedule Monday and Thursday)	3 days	Serum preferred or Li-heparin*, citrate or EDTA plasma
HIV I & II antibody (LIA) – saliva (Tests schedule Monday and Thursday)	3 days	Saliva
HIV-1 proviral LTR, env, gag and pol genes	2 days	EDTA whole blood preferred or serum/plasma, CSF A paired maternal blood sample should be sent when testing infants <18 months old for HIV-1 proviral DNA / RNA.
HIV-1 RNA drug resistance ♦	9 days	Serum/plasma. <b>This test requires at least 600µL of sample. Please supply viral load if available.</b>
HIV-1 RNA Integrase drug resistance ♦	9 days	Serum/plasma. <b>This test requires at least 600µL of sample. Please supply viral load if available.</b>
HIV-1 RNA quantitation ♦	3 days	EDTA Plasma, CSF. <b>Please supply 2mL EDTA plasma.</b>
HIV-2 proviral LTR and pol DNA/RNA	2 days	EDTA whole blood preferred or serum/plasma, CSF
HTLV I & II antibody	Tests scheduled Wednesdays	Serum preferred or EDTA, citrate plasma

Tests available		
Test	Target turn-around	Validated Sample types
HTLV DNA or RNA	3 days	EDTA/citrated whole blood, serum, plasma or CSF
Human Herpesvirus 6A and 6B DNA	Next day	EDTA/citrated whole blood (CSF in encephalitis), bone marrow biopsies, , plasma, serum
Human Herpesvirus 6 DNA quantitation	Next day	EDTA/citrated whole blood (CSF in encephalitis), bone marrow, plasma, serum
Human Herpesvirus 7 DNA	Next day	EDTA/citrated whole blood, CSF. Plasma or serum may be tested but whole blood is preferred.
Human Herpesvirus 7 DNA quantitation	Next day	EDTA/citrated whole blood, CSF. Plasma or serum may be tested but whole blood is preferred.
Human Herpesvirus 8 DNA	Next day	EDTA/citrated whole blood. Plasma or serum may be tested but whole blood is preferred.
Human Herpesvirus 8 DNA quantitation	Next day	EDTA/citrated whole blood. Plasma or serum may be tested but whole blood is preferred.
Human Papillomavirus DNA detection	5 days	Swab, tissue (including fixed). Please state site of swab / tissue type. For genital samples: Female: Endocervical swab sent in VTM or 'thin prep' endocervical cellular specimens. Male: Penile swab placed into VTM or fresh biopsy tissue.
Human Papillomavirus DNA typing	5 days	Any positive detected from samples detailed for HPV detection.
Human Papillomavirus DNA <b>high risk typing (Genital samples only)</b>	5 days	Female: Endocervical swab sent in VTM or 'thin prep' endocervical cellular specimens. Male: Penile swab placed into VTM.
IL28B gene (rs12979860)	4 days	EDTA / citrated whole blood
Influenza A virus RNA	Same day	Any upper / lower respiratory specimen
Influenza B virus RNA	Same day	Any upper / lower respiratory specimen
Legionella pneumophila ▲	Same day	Any upper / lower respiratory specimen
Leptospira genus DNA	3 days	CSF, EDTA/citrated whole blood, urine
Lymphogranuloma venereum <i>All LGV requests are also tested for Ct and Ng.</i>	4 days	Male - first catch urine, genital swab, rectal swab, throat swab, rectal biopsy/tissue, lymph node tissue/biopsy. Female - genital swab, throat swab, rectal swab, rectal biopsy/tissue, lymph node tissue/biopsy
Listeria monocytogenes DNA	Next day	CSF, EDTA/citrated whole blood - may be useful in suspected meningitis cases
Measles virus RNA	Next day	CSF, urine, saliva, mouth/throat swab, whole blood, amniotic fluid

Tests available		
Test	Target turn-around	Validated Sample types
Mumps IgG antibody	Tests schedule Wednesdays	Serum preferred or citrate plasma
Mumps virus RNA	Next day	CSF, urine, saliva, mouth/throat swab
Mycobacterium avium complex\TB complex DNA	4 days	Sputum, tissue, fixed tissue, CSF, BAL, culture
Mycobacterium genus DNA	4 days	Sputum, tissue, fixed tissue, CSF, BAL, culture
Mycobacterium TB rifampicin resistance	3 days	Sputum, tissue, fixed tissue, CSF, BAL, culture
Mycoplasma genitalium DNA	2 days	Urine/genital swab
Mycoplasma genitalium macrolide resistance ▲ All <i>Mycoplasma genitalium</i> macrolide requests are also tested in-house for confirmation of Mycoplasma genitalium positivity	4 days	Urine/genital swab
Mycoplasma genus DNA	4 days	CSF, EDTA/citrated whole blood, tissue culture
Mycoplasma pneumoniae DNA See Ⓞ below (▲NxTAG® results only)	Next day	EDTA whole blood, BAL and NPA
Neisseria gonorrhoeae DNA Individual requests for Ng are always tested in combination with Ct respectively. If sending for confirmation in accordance with BASHH guidelines, please telephone the laboratory for further information.	2 days	Eye swab For genitourinary: Female: Endocervical, vaginal or rectal swab, 'Thin prep' endocervical cellular specimens. Male: Urethral swab, first pass urine, rectal swab
Neisseria meningitidis DNA ▲	Same day	CSF, EDTA/citrated whole blood (may be useful in suspected meningitis cases), swabs, joint fluid
Neisseria meningitidis DNA typing	2 days	Performed routinely on positive Neisseria meningitidis samples
Parainfluenza 1,2,3 and 4 virus RNA	Same day	Any upper / lower respiratory specimen
Parechovirus RNA	Next day	CSF, swab, stool, tissue, serum, plasma, EDTA/citrated whole blood - may be useful in suspected meningitis cases
Parvovirus B19 DNA	Next day	EDTA/citrated whole blood, amniotic fluid, serum/plasma, post-mortem samples (Foetal), CSF, bone marrow
Parvovirus B19 DNA quantitation	Next day	EDTA/citrated whole blood, amniotic fluid, serum/plasma, CSF

Tests available		
Test	Target turn-around	Validated Sample types
Pneumocystis jirovecii (aka carinii) DNA ▲	Next day	Sputum, BAL, NPA preferred.
Polyoma BK virus DNA ▲	Next day	EDTA/citrated whole blood, urine
Polyoma BK virus DNA quantitation ▲	Next day	EDTA/citrated whole blood, urine
Polyoma JC virus DNA	Next day	EDTA/citrated whole blood, urine, CSF
Polyoma JC virus DNA quantitation	Next day	EDTA/citrated whole blood, urine, CSF
Propionibacteria/Actinomyces DNA	2 days	Eye sample, tissue, CSF
Pseudomonas aeruginosa ▲	Next day	EDTA whole blood, corneal scrape, eye swab, contact lens or contact lens solution
Respiratory Syncytial Virus RNA	Same day	Any upper / lower respiratory specimen
Respiratory Virus Screen <b>See ☉ below</b>	Next day	Any upper / lower respiratory specimen
Extended respiratory screen. Respiratory screen detailed above with additional Coronavirus OC43, 229E, NL63, HKU1 and SARS-CoV-2 testing	Next day	Any upper / lower respiratory specimen
Rhinovirus RNA	Same day	Any upper / lower respiratory specimen
Rhinovirus typing (Research only)	3 days	Any positive Rhinovirus respiratory specimen
Rubella virus RNA	Next day	CSF, EDTA/citrated whole blood, throat swab, urine, amniotic fluid
Salmonella enterica (Research only)	Next day	CSF, EDTA/citrated whole blood – may be useful in suspected meningitis cases, tissue, abscess fluid.
Staphylococcus genus DNA	Next day	CSF, aqueous/vitreous humour, tissue
Streptococcus pneumoniae DNA	Same day	Whole blood, CSF and pleural fluid
Toxoplasma gondii DNA	Same day	CSF, EDTA/citrated whole blood, amniotic fluid, aqueous/vitreous humours, tissue
Toxoplasma IgG antibody (Tests schedule Monday and Thursday)	5 days	Serum preferred or Li-heparin*, K3-EDTA or citrate plasma
Treponema pallidum DNA	2 days	CSF, genital swab
Trichomonas vaginalis DNA	2 days	Genital swab
Tropheryma whipplei DNA	Next day	CSF and almost any cellular material including whole blood. <b>PLEASE DO NOT SEND SERUM.</b>
Ureaplasma urealyticum/parvum DNA	2 days	Urine, genital swab, respiratory (neonates)
Varicella Zoster virus DNA	Next day	CSF, AC tap, EDTA/citrated whole blood, corneal scrape, vesicle fluid, skin/eye/vesicle/lesion swab, tissue (Biopsy and fixed included).

Tests available		
Test	Target turn-around	Validated Sample types
		Any respiratory specimen (sputum, BAL, NPA, nasopharyngeal swab etc), aqueous / vitreous humour. Genitourinary - For female: Endocervical or vulval lesions sample area with a swab and place into viral transport media (VTM). Male: Penile lesions - Penile swab placed into VTM Pregnancy – vulval/vaginal swab
West Nile Fever virus RNA ▲	Next day	CSF, EDTA whole blood

#### Key for test table

▲ Currently awaiting UKAS accreditation. Some tests results reported for *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* are generated using the NxTAG® Respiratory Pathogen Panel. This is a validated test and is awaiting further UKAS accreditation for these two tests.

◆ EDTA Plasma separated within 24 hours of initial collection of blood. Ship at ambient temperature for next day delivery.

\* - Li Heparin/Na heparin has inhibitory effects in PCR. Please provide an alternative sample if molecular detection of viral / bacterial / fungal targets or human genetics tests are required.

\*\* - For the Hepatitis B surface antibody assay, if plasma treated with lithium heparin, sodium citrate, sodium fluoride or potassium oxalate is used, values obtained are 25% lower compared with serum. Additionally, lithium heparin plasma tubes containing separating gel should not be used for this test.

\*\*\* - Serum and plasma may be tested but whole blood is preferred.

⊖- Respiratory panel comprising of Influenzae A and B, Respiratory syncytial virus A and B, Parainfluenza 1 – 4, Human metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Human Bocavirus.

The extended respiratory screen is comprised of the aforementioned organisms with Coronavirus OC43, 229E, NL63, HKU1 and new Coronavirus-SARS-CoV-2 additional testing. Please note, Influenza A positives▲ can be differentiated between H1 and H3 subtypes. If required this can be reported. Differentiation of Rhinovirus/Enterovirus will incur an extra day TAT to facilitate additional testing. Mycoplasma pneumoniae and Chlamydia pneumoniae positives may be reported following testing on the NxTAG® Respiratory Pathogen Panel.

Ψ Please note; when Measles RNA, Rubella RNA, *Neisseria meningitidis* DNA or *Bordetella pertussis* DNA are detected within a specimen, the sample will be forwarded to Public Health England to comply with their requirements.



## 3.8 Factors affecting assays

### 3.8i Nucleic acid based tests

The sensitivity of DNA/RNA detection tests depends on the quality/type of the sample and the test performed.

#### *Low volume samples*

The laboratory may receive low volume samples. However, these may be diluted for extraction and testing. The result report will bear a suitable caveat alerting the user to this. It is recommended that users send the required volume for extraction and testing.

#### *Extracted samples*

These samples extracted elsewhere may be subject to testing but the laboratory cannot guarantee the efficiency of detection in the laboratory assays on samples extracted by a procedure not validated by ourselves. Extracts of insufficient volume may also be subject to dilution for testing.

#### *Li-heparin or Na-heparin whole blood samples*

Li Heparin/Na heparin has inhibitory effects in PCR. Please provide an alternative sample if molecular detection of viral / bacterial targets or human genetics tests are required. EDTA samples are preferred.

#### *Inhibitory samples*

All clinical samples are processed with a nucleic acid extraction procedure that has been shown to overcome the potential inhibition of assays associated with some samples.

Urine samples however, may still contain enough inhibitors, even after extraction, to affect the detection of low levels of target nucleic acid.

We are able to detect if inhibition has occurred and we report accordingly.

#### *Sample instability*

Significant delay in sending and/or receiving samples can result in sample instability and thus may hinder detection of the requested target.

#### *Handling samples for HIV-1, HBV and HCV*

For test requests on HCV, HBV detection, drug resistance, genotyping and quantitation and/or HIV drug resistance and quantitation, please supply separated plasma. When separating plasma from EDTA whole blood by centrifugation, please perform the separation within 24 hours of sample collection.

This is important to provide accurate viral load measurements of cell-free circulating infectious virus. The presence of red blood cells in EDTA plasma samples indicates the possible presence of white blood cell contamination. This may affect the results

of HIV-1 viral load assays. Additionally HIV-1, HBV and HCV viruses are subject to degradation in blood samples in which plasma is not separated within the 24hour from blood draw which can lead to inaccurate qualitative and quantitative results.

If samples are not separated before sending to Micropathology Ltd., please ensure arrangements are in place to send the sample to us within 24 hours of collection to prevent virus degradation during transit.

Separated plasma samples should not be frozen if there is to be a short delay between separation and sending to the laboratory, as freeze-thawing samples can result in virus DNA/RNA degradation. If a delay in sending the sample is unavoidable, please refrigerate the plasma and send it to us via an appropriate cold-chain courier.

### 3.8 ii Serology samples

Fresh blood in plain or gel tubes is best left at room temperature to clot. **DO NOT FREEZE or OVER COOL ANY WHOLE BLOOD SAMPLES** as this may result in haemolysis of the red blood cells. This is particularly important as severe haemolysis of red blood cells may compromise the results of serology assays.

Antibodies and antigens are only stable for a particular length of time after sample taking and serum separation. Please take note of the test table below and the scheduling of the serology assays to ensure that samples are transported to ensure the integrity of the sample.

Assay	Sample stability
Aspergillus antigen (Galactomannan)	Serum – Unopened samples 5 days 2 - 8°C, opened samples 2 days 2 – 8°C. Serum can be stored long term at -70°C. BAL – after initial opening 24hrs at 2-8°C. BAL can be stored long term -20°C for 5 mths
HCV antibodies	ELISA 3 days (25°C), 7 days (2 - 8°C), 3 mths (-20°C) RIBA 7 days 2-8°C, long term -20°C or lower.
HIV I and II antibodies	ELISA 7 days (25°C), 4 weeks (2 - 8°C), 3 mths (-20°C) LIA 7 days 2-8°C, long term -20°C or lower.
HBV surface antigen	5 days (2 - 8°C), 3 mths (-20°C)
HBV sAg quantitation	7 days (2 - 8°C), 3 mths (-20°C)
HBV Core antibody	7 days (15-25°C), 14 days (2 - 8°C), 3 mths (-20°C)
HBV E Antigen	7 days (20-25°C), 14 days (2 - 8°C) (plasma), 11 days (2 - 8°C) (serum) 3 mths (-20°C) (both)
HBV E antigen antibodies	7 days at 20-25 °C, 14 days at 2-8°C, 3 mths at -20 °C (± 5 °C).
HBV surface antibodies	3 days (20-25°C), 6 days (2 - 8°C), 3 mths (-20°C)
HTLV 1 and 2 antibodies	7 days 2-8°C, long term -15°C or lower.
Measles IgG antibodies	5 days 2-8°C, long term -20°C to -70°C.
Mumps IgG antibodies	5 days 2-8°C, long term -20°C to -70°C.
Toxo IgG antibody	3 days (25°C), 3 weeks (2 - 8°C), 3 mths (-20°C)

### 3.9 Criteria for accepting / rejecting samples

Samples are accepted for testing if they are:

- 1 Of appropriate sample type for tests required, as detailed in this handbook (pages 15-24).
- 2 Of sufficient volume for testing.
- 3 Correctly matched information on sample and request form.
- 4 Sufficient patient/source identification (Table on page 12).

Samples maybe rejected if:

- 1 Inappropriate sample type.
- 2 Leakage has occurred.
- 3 Low volume\*.
- 4 Badly haemolysed (serum/plasma samples for HIV-1 Quant and serological assays).
- 5 Misdirected\*\*.
- 6 Mismatched sample and request form\*\*.
- 7 Insufficient or incorrect information on sample and / or request form.

If any of the above rejected samples are tested, result reports will bear an appropriate caveat indicating the nature of the problem (if sample related) and that results should be interpreted with caution. If the sample is rejected and not subject to testing, the referring laboratory will be notified of the rejection of the sample and reasons why, by either telephone or email.

\*Samples will be rejected outright if they appear to contain no sample. Users will be contacted.

\*\*Micropathology Ltd will contact clients if samples are misdirected, contain insufficient / incorrect information or have a mismatched sample / request form.

### 3.10 Reference values for Serological assays

Reference values for serology assays provided at Micropathology Ltd are detailed below.

#### Qualitative assays

TEST	Cut-off	Reactive	Non-reactive	Borderline
Anti-HCV	1.0	≥ 1.0	< 0.9	≥ 0.9 - < 1.0
HIV combi	1.0	≥ 1.0	< 0.9	≥ 0.9 - < 1.0
HBsAg II	1.0	≥ 1.0	< 0.9	≥ 0.9 - < 1.0
Anti-HBc	1.0	≤ 1.0	> 1.0	
Anti-HBe	1.0	≤ 1.0	> 1.0	
HBeAg	1.0	≥ 1.0	< 1.0	
Aspergillus antigen Galactomannan	0.5			

## Semi-quantitative

TEST	Not detected	Detected	Equivocal
Mumps IgG	<9 U/mL	>11 U/mL	9-11 U/mL

## Quantitative assays

TEST	Measuring Range	Reactive	Non-reactive	Equivocal	Dilution
Toxoplasma	0.13 – 650 IU/mL (13,000 IU/mL if diluted 1:20)	≥ 3 IU/mL	< 1 IU/mL	≥ 1 - < 3 IU/mL	Samples >650 IU/mL can be diluted 1:20
Anti-HBs	2.00 – 1,000 IU/L (100,000 if diluted 1:100)	≥ 10 IU/L	< 10 IU/L		Samples >1,000 IU/L can be diluted 1:100
HBsAg II quant	5 – 13,000 IU/mL for 100-fold diluted samples (mandatory). 0.05 – 130 IU/mL for undiluted samples.	>0.05	Values of < 0.05 are considered to be below the Limit of Detection.		It is mandatory for samples to be diluted on-board at 1:100. Samples >13,000 IU/mL can be further diluted manually 1:100 to achieve a final 1:10,000 dilution.

Please contact the laboratory for additional information regarding these reference values.

### 3.11 Human genetic testing

Genetic services provide the following tests:

- Genetic profiling for human identification and relationship testing
- Haemochromatosis: HFE Gene Mutations
- Prothrombin and Factor V Mutations
- IL28B gene (rs12979860 polymorphism associated response to the combination of pegylated-interferon and ribavirin for the treatment of HCV)
- Alpha-1 antitrypsin deficiency genotyping.

A minimum of 200µL (preferably 500µL to facilitate additional extraction and testing) of EDTA or citrated whole blood is required for these tests with the exception of genetic profiling for human identification and relationship testing, which can be performed on various sample types. Please contact the laboratory for advice.

In addition to the specific tests listed, our molecular genetic services are also available for contract research projects in any relevant area of human or animal diagnosis and screening. We would be very pleased to hear from prospective clients who may have requirements for specific genetic tests.

### 3.11i Consent for Genetic Testing

It is the responsibility of the clinician requesting a genetic test to obtain informed consent for testing from the patient or an individual with parental/legal responsibility for the patient. Guidelines on consent for genetic testing are provided by the Joint Committee on Medical Genetics and are available at [http://www.bsgm.org.uk/media/39563/consent\\_and\\_confidentiality\\_2011\\_1\\_.pdf](http://www.bsgm.org.uk/media/39563/consent_and_confidentiality_2011_1_.pdf)

When sending samples for testing family relationships, such as paternity or maternity testing, sibship analysis and twin zygosity testing, please clearly describe the suspected relationships including half-sibship status and provide full names and dates of birth of all individuals involved to avoid unnecessary confusion or delays caused by the need to carry out extensive fact checking.

### **3.12 Sequencing service**

Micropathology Ltd provides the following sequencing services in support of the diagnosis and management of infectious disease:

- Adenovirus typing
- Cytomegalovirus ganciclovir, foscarnet and cidofovir resistance
- Enterovirus typing
- HBV Genotyping
- HBV drug resistance mutation screening
- HCV Genotyping
- HCV NS5A drug resistance
- Herpes Simplex Acyclovir drug resistance
- HIV-1 RT/Protease/Integrase drug resistance mutation analysis
- HPV genotyping
- Rhinovirus typing
- 16srRNA and 18srRNA gene sequencing for species determination
- *Mycobacterium tuberculosis* Rifampicin resistance
- *Mycobacterium* genus
- *Mycoplasma* genus
- *Mycoplasma genitalium* Macrolide resistance

Please refer to the list of tests and sample types for further information regarding suitable sample types.

## **4. Additional services**

- Cell culture reagent testing for infection
- Medico-legal investigations of infection or genetic studies
- Contract and collaborative research services

Please see our web site for further information

## 5. Quality Assurance

### 5.1 External QA schemes

We took part in the following external quality assurance schemes (2019):

#### United Kingdom National External Quality Assessment Service

- Anti-HBsAg
- Blood-Borne Virus donor screen (serology for hepatitis C Ag and AB, hepatitis B (HBVSAg, Anti-HBV Core), HIV 1 and 2 Ag and AB (including p24), HTLV 1 and 2 AB
- Fungal biomarkers
- HepB serology (Surface antigen, 'e' antigen, 'e' antibody, core antibody)
- HFE (Haemochromatosis) H63D, C282Y & S65C mutations
- Thrombophilia gene mutations (Factor V Leiden & Prothrombin)
- Measles & mumps IgG
- Molecular tissue identification
- Mycobacteria (molecular)
- Mycology (Molecular fungal identification)
- Toxoplasma IgG

#### INSTAND panels

- IL-28B
- Alpha-1 antitrypsin
- Rubella RNA
- *Coxiella burnetii* DNA
- *Salmonella* sp. detection
- *Brucella* sp. DNA
- HIV-2 detection

#### Quality Control for Molecular Diagnostics

- Adenovirus DNA quantitation
- CMV DNA qualitative dry blood spot
- CMV DNA quantitation (whole blood)
- CMV drug resistance (UL97/UL54)
- EBV DNA quantitation (whole blood)
- Enterovirus RNA
- HBV DNA quantitation
- HBV drug resistance
- HBV genotyping
- HCV drug resistance
- HCV genotyping
- HCV RNA quantitation

- HDV RNA quantitation
- HEV RNA quantitation
- HHV6 DNA quantitation
- HIV-1 DNA/RNA
- HIV-1 drug resistance (protease/reverse transcriptase / integrase)
- HIV-1 RNA quantitation
- HPV
- HSV
- HSV drug resistance
- influenza virus A and B
- measles
- mumps
- parechovirus
- parvovirus B19
- polyoma virus BK
- polyoma virus JC
- Respiratory II (MPV, Adenovirus, Rhinovirus, coronavirus, enterovirus, parainfluenza viruses 1-4).
- RSV
- VZV
- West Nile virus
  
- *Aspergillus spp.*
- Bacterial 16S panel
- Bacterial sepsis (*Staphylococcus*, *Serratia*, *Escherichia coli*, *Staphylococcus*, *Enterococcus*, *Streptococcus* and *Klebsiella*, *Pseudomonas*)
- *Bordetella pertussis*
- *Borrelia burgdorferi*
- *Candida spp.*
- Central nervous system II (*Listeria spp.*, *Neisseria meningitides*, *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *Escherichia coli*, *Aspergillus spp.*, *Haemophilus influenzae* strains)
- *Chlamydia pneumoniae*
- *Chlamydia psittacii*
- *Chlamydia trachomatis*
- Group B *Streptococcus*
- *Mycobacterium tuberculosis*
- *Mycoplasma pneumoniae*
- *Mycoplasma sp.*
- *Neisseria gonorrhoeae*
- Non-tuberculosis *Mycobacteria spp.*
- *Pneumocystis jirovecii*
- STI screen (*Mycoplasma genitalium*, *Ureaplasma sp.*, *Trichomonas vaginalis*, *Mycoplasma hominis*, *Gardnerella vaginalis*)
- Respiratory III (*Pertussis*, *Legionella pneumoniae*, *Mycoplasma pneumoniae*, *Streptococcus pneumoniae*, *Haemophilus influenzae* strains)
- *Toxoplasma gondii*

- *Treponema pallidum*

## Veterinary laboratory agency

- Leptospira genus

## Informal interlaboratory exchange schemes 2019 included:

- *Tropheryma whipplei*
- Group A *Streptococcus* – *Streptococcus pyogenes*
- *Propionibacterium acnes*

## 5.2 Accreditation

Micropathology Ltd is an accredited medical laboratory to ISO15189:2012 standard. UKAS Reference Number: 9622. UKAS provides a means to accredit Medical Laboratories and External Quality Assessment Schemes (EQA) and involves an external audit of the ability to provide a service of high quality by declaring a defined standard of practice, which is confirmed by peer review.

For all Quality Management System enquiries please contact Dr Andrea Collins on [a.collins@micropathology.com](mailto:a.collins@micropathology.com).

## 6. Results and Reports

Results are transmitted to users between 16:00 and 18:00 Monday to Friday with the exception of any SARS CoV-2 test results from any pre-arranged weekend testing. These will be transmitted to users on Saturday or Sunday when results are approved.

The primary delivery method of results is to pre-specified email address as a PDF attachment. Where a single email address is specified, it is strongly recommended that multiple users have access to this mailbox.

If you have not referred anything to us on a routine basis please contact [info@micropathology.com](mailto:info@micropathology.com) or telephone +44 (0) 2476 323222, to confirm we hold the correct result destinations (Fax numbers, email addresses etc). Additionally, please contact the laboratory to alter any current report destinations.

It may be important to transmit the results of a test as soon as possible e.g. positive test results of clinical significance or where the results of an examination falls within a critical interval. The referring laboratory will be alerted of these results as soon as the test operator has entered them into LIMS and requested their immediate authorisation.

Results are **only** provided over the telephone to the **requesting laboratory** with the exception of results for HIV-1/2 diagnosis, HIV-1 RNA quantitation and any sexual



health transmitted diseases (CtNg, T. pallidum, HSV on genital swabs, Haemophilus ducreyi, Mycoplasma genitalium, Ureaplasma urealyticum / parvum). These are not provided over the telephone and callers are asked to contact the referring laboratory for details of the final authorised report.

If you are contacting us from the source of the primary sample and not the referring laboratory, we request that you contact the referring laboratory for the results provided in the final report.

## **7. User Feedback and Complaints procedure**

Feedback and Complaints regarding the service provided by Micropathology Ltd (Companies house registration No. 3022426) can be made via the following routes:

1. Contact the laboratory directly by telephoning 024 76323222
2. Email the Quality Manager Dr Andrea Collins, [a.collins@micropathology.com](mailto:a.collins@micropathology.com)
3. Email the laboratory, [info@micropathology.com](mailto:info@micropathology.com)
4. Email/contact the company representative, Miss Heather Smith, [heather.smith@micropathology.com](mailto:heather.smith@micropathology.com)

## **8. Payment for services**

### **8.1 Terms of Payment**

Invoices are issued at the end of each month and work is completed on the basis of an undertaking by the Client to ensure payment within 30 working days (6 weeks) from the date of the invoice. Since August 2018 any invoices not paid within this time may incur a 25% surcharge.

### **8.2 Acceptable Methods of payment**

BACs is the preferred method of payment.